{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:22:55Z","timestamp":1707524575904},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,8]]},"DOI":"10.7759\/cureus.25743","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T08:35:41Z","timestamp":1654677341000},"source":"Crossref","is-referenced-by-count":0,"title":["The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome"],"prefix":"10.7759","author":[{"given":"Mariana S","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abel","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Cabral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris M","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, et al.. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010, 5:1844-59. 10.2215\/CJN.02210310","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1262889","article-title":"New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab","volume":"36","author":"K\u00f6se O","year":"2010","unstructured":"K\u00f6se O, Zimmerhackl LB, Jungraithmayr T, Mache C, N\u00fcrnberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost. 2010, 36:669-72. 10.1055\/s-0030-1262889","journal-title":"Semin Thromb Hemost"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone J","year":"2013","unstructured":"Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. 2013, 3:e003573. 10.1136\/bmjopen-2013-003573","journal-title":"BMJ Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-019-04233-7","article-title":"Hemolytic uremic syndrome in a developing country: consensus guidelines","volume":"34","author":"Bagga A","year":"2019","unstructured":"Bagga A, Khandelwal P, Mishra K, et al.. Hemolytic uremic syndrome in a developing country: consensus guidelines. Pediatr Nephrol. 2019, 34:1465-82. 10.1007\/s00467-019-04233-7","journal-title":"Pediatr Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-008-0872-4","article-title":"Complement and the atypical hemolytic uremic syndrome in children","volume":"23","author":"Loirat C","year":"2008","unstructured":"Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008, 23:1957-72. 10.1007\/s00467-008-0872-4","journal-title":"Pediatr Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2015.07.005","article-title":"An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document","volume":"35","author":"Campistol JM","year":"2015","unstructured":"Campistol JM, Arias M, Ariceta G, et al.. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2015, 35:421-47. 10.1016\/j.nefro.2015.07.005","journal-title":"Nefrologia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.20344\/amp.10021","article-title":"Diagnostic and Therapeutic Challenges in Atypical Hemolytic Uremic Syndrome: A Case Report (Article in Portuguese)","volume":"32","author":"Reis S","year":"2019","unstructured":"Reis S, Ramos D, Cordinh\u00e3 C, Gomes C. Diagnostic and Therapeutic Challenges in Atypical Hemolytic Uremic Syndrome: A Case Report (Article in Portuguese). Acta Med Port. 2019, 32:673-5. 10.20344\/amp.10021","journal-title":"Acta Med Port"},{"key":"ref8","article-title":"UpToDate","author":"Niaudet P","year":"2022","unstructured":"Niaudet P, Gillion Boyer O. UpToDate . Complement-mediated hemolytic uremic syndrome in children. Mattoo TK (ed): UpToDate, Waltham, MA; 2022."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome","volume":"360","author":"Gruppo RA","year":"2009","unstructured":"Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009, 360:544-6. 10.1056\/NEJMc0809959","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht C","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, et al.. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015, 87:1061-73. 10.1038\/ki.2014.423","journal-title":"Kidney Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.07.028","article-title":"Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab","volume":"61","author":"Schmidtko J","year":"2013","unstructured":"Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis. 2013, 61:289-99. 10.1053\/j.ajkd.2012.07.028","journal-title":"Am J Kidney Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat C","year":"2011","unstructured":"Loirat C, Fr\u00e9meaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011, 6:60. 10.1186\/1750-1172-6-60","journal-title":"Orphanet J Rare Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris M","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009, 361:1676-87. 10.1056\/NEJMra0902814","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli J","year":"2006","unstructured":"Caprioli J, Noris M, Brioschi S, et al.. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006, 108:1267-79. 10.1182\/blood-2005-10-007252","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12763","article-title":"Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment","volume":"23","author":"Raina R","year":"2019","unstructured":"Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019, 23:4-21. 10.1111\/1744-9987.12763","journal-title":"Ther Apher Dial"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000508920","article-title":"Atypical hemolytic uremic syndrome: new challenges in the complement blockage era","volume":"144","author":"Avila Bernabeu AI","year":"2020","unstructured":"Avila Bernabeu AI, Cavero Escribano T, Cao Vilarino M. Atypical hemolytic uremic syndrome: new challenges in the complement blockage era. Nephron. 2020, 144:537-49. 10.1159\/000508920","journal-title":"Nephron"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre CM","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, et al.. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013, 368:2169-81. 10.1056\/NEJMoa1208981","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/97074-the-importance-of-eculizumab-in-the-treatment-of-atypical-hemolytic-uremic-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:44:32Z","timestamp":1707507872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/97074-the-importance-of-eculizumab-in-the-treatment-of-atypical-hemolytic-uremic-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.25743","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,8]]}}}